David C. Raphael Jr.

David Raphael joined the firm in 2006 as an associate and is currently a partner specializing in antitrust litigation. Mr. Raphael represents direct purchasers in numerous antitrust matters, including In re King Drug Company Of Florence, Inc. et al v. Abbott Laboratories et al (AndroGel), 19cv3565 (E.D. Pa.); In re Louisiana Wholesale Drug Co., Inc. v. Smithkline Beecham Corporation et al (Lamictal), 2:12cv995 (D. NJ) (both of which are joinder actions), and In re Niaspan Antitrust Litigation, No. 2:13-md-02460 (E.D. Pa.), a certified class action. He was an active member of the trial team for the class in the King Drug Company of Florence, Inc. et al. v. Cephalon, Inc., et al (Provigil), No. 2:06-cv-1797 (E.D. Pa.); In re Namenda Direct Purchaser Antitrust Litigation, 1:15cv7488 (S.D.N.Y.); In Re: Opana ER Antitrust Litigation,1:14-cv-10150 (N.D. Ill.); and In re Value Drug Company v. Takeda Pharmaceuticals, U.S.A., Inc. et al (Colcrys), 2:21cv3500 (E.D. Pa.). 

Mr. Raphael also has experience litigating class action cases involving RICO and government regulatory misconduct, including In re EpiPen Direct Purchaser Litigation, 0:20-cv-00827 (D. Minn.) and Donald W. Abshire, et al v. The State of Louisiana, et al, No. 377,713 c/w 412,265; 19th J.D.C., State of Louisiana, in which a multi-million-dollar recovery was obtained for the certified class of hundreds of claimants, with Mr. Raphael serving as co-lead class counsel.

Mr. Raphael is a native of New Orleans. He received his undergraduate and law degrees from Louisiana State University (B.S. 1989; J.D. 1993). He is licensed to practice law in Louisiana, and has been admitted to practice in the United States Supreme Court; the United States Courts of Appeals for the Federal, Third and Fifth Circuits; and the United States District Courts for the Eastern, Middle and Western Districts of Louisiana.